| 臺大學術典藏 |
2020-03-05T12:32:51Z |
Kr?ppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma
|
Chang V.H.S.; Chu P.-Y.; Peng S.-L.; TSUI-LIEN MAO; Shan Y.-S.; Hsu C.-F.; Lin C.-Y.; Tsai K.K.C.; Yu W.C.Y.; Ch'Ang H.-J. |
| 臺北醫學大學 |
2012 |
Kr?ppel-like factor 10 upregulates the expression of cyclooxygenase 1 and further modulates angiogenesis in endothelial cell and platelet aggregation in gene-deficient mice
|
Diane, H.A.Yang;Hsu, Ching-Fang;Lin, Chun-Yu;Guo, Jia-Yi;Winston, C.Y.Yu;Vincent, H.S.Chang |
| 亞洲大學 |
2007-04 |
Kr?ppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion
|
Xianhui Wang;Mingzhe Zheng;Gang Liu;Weiya Xia;Paula J. Mckeown-Longo;Mien-Chie Hung;Jihe Zhao |
| 臺大學術典藏 |
2020-02-17T07:43:40Z |
Kr?ppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells
|
Wong C.-W; Hou P.-S; Tseng S.-F; Chien C.-L; Wu K.-J; Chen H.-F; HONG-NERNG HO; Kyo S; Teng S.-C. |
| 臺大學術典藏 |
2022-04-15T03:14:26Z |
Kr?ppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells
|
Huang Y.-C.; Chen H.-T.; SHU-CHUN TENG |
| 淡江大學 |
2005-06 |
Krachschlagen: Versuch �ber Elfriede Jelineks Prosa
|
狄殷豪 |
| 國立臺灣科技大學 |
2018 |
Kraft lignin biorefinery: A perspective
|
Hu, J.;Zhang, Q.;Lee, D.-J. |
| 國立臺灣科技大學 |
2018 |
Kraft lignin biorefinery: A perspective
|
Hu, J.;Zhang, Q.;Lee, D.-J. |
| 嘉南藥理大學 |
2009 |
Krankenhaus-Hygiene + Infektionsverh�
|
Elsevier SDOL |
| 國立臺灣大學 |
2015 |
KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation
|
Serrano, Cesar; Wang, Yuexiang; Marino-Enriquez, Adrian; Lee, Jen-Chieh; Ravegnini, Gloria; Morgan, Jeffrey A.; Bertagnolli, Monica M.; Beadling, Carol; Demetri, George D.; Corless, Christopher L.; Heinrich, Michael C.; Fletcher, Jonathan A.; 李仁傑 |
| 臺大學術典藏 |
2018-09-10T15:28:15Z |
KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation
|
Serrano, C. and Wang, Y. and Mari\\~no-Enr\\'iquez, A. and Lee, J.-C. and Ravegnini, G. and Morgan, J.A. and Bertagnolli, M.M. and Beadling, C. and Demetri, G.D. and Corless, C.L. and Heinrich, M.C. and Fletcher, J.A.; JEN-CHIEH LEE |
| 臺大學術典藏 |
2020-03-07T06:52:12Z |
KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation
|
Serrano C.;Wang Y.;Mariño-Enríquez A;Jen-Chieh Lee;Ravegnini G.;Morgan J.A.;Bertagnolli M.M.;Beadling C.;Demetri G.D.;Corless C.L.;Heinrich M.C.;Fletcher J.A.; Serrano C.; Wang Y.; Mariño-Enríquez A.; JEN-CHIEH LEE; Ravegnini G.; Morgan J.A.; Bertagnolli M.M.; Beadling C.; Demetri G.D.; Corless C.L.; Heinrich M.C.; Fletcher J.A. |
| 臺大學術典藏 |
2015 |
KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation
|
Serrano C.; Wang Y.; Mari?o-Enr?quez A.; JEN-CHIEH LEE; Ravegnini G.; Morgan J.A.; Bertagnolli M.M.; Beadling C.; Demetri G.D.; Corless C.L.; Heinrich M.C.; Fletcher J.A. |
| 國立成功大學 |
2017-07-26 |
KRAS Gene Mutations在大腸直腸癌肝轉移中扮演的角色
|
林鵬展; Lin, Peng-Chan |
| 臺大學術典藏 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; JAU-YU LIAU; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 國立臺灣大學 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin, Yu-Lin; Liau, Jau-Yu; Yu, Shan-Chi; Ou, Da-Liang; Lin, Liang-In; Tseng, Li-Hui; Chang, Yih-Leong; Yeh, Kun-Huei; Cheng, Ann-Lii; 林亮音; 曾麗慧; 張逸良; 林育麟; 鄭安理; 葉坤輝; 歐大諒; 尤善琦; 廖肇裕 |
| 臺大學術典藏 |
2018-09-10T09:22:43Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin, Yu-Lin;Liau, Jau-Yu;Yu, Shan-Chi;Ou, Da-Liang;Lin, Liang-In;Tseng, Li-Hui;Chang, Yih-Leong;Yeh, Kun-Huei;Cheng, Ann-Lii; Lin, Y.-L. and Liau, J.-Y. and Yu, S.-C. and Ou, D.-L. and Lin, L.-I. and Tseng, L.-H. and Chang, Y.-L. and Yeh, K.-H. and Cheng, A.-L.; 林亮音 ;曾麗慧 ;張逸良 ;林育麟 ;鄭安理 ;葉坤輝 ;歐大諒 ;尤善琦 ;廖肇裕; 林亮音 ;曾麗慧 ;張逸良 ;林育麟 ;鄭安理 ;葉坤輝 ;歐大諒 ;尤善琦 ;廖肇裕; Lin, Yu-Lin; LI-HUI TSENG; Lin, Yu-Lin; Liau, Jau-Yu; YIH-LEONG CHANG; JAU-YU LIAU; Yu, Shan-Chi; Ou, Da-Liang; DA-LIANG OU; Ou, Da-Liang; LIANG-IN LIN; Lin, Liang-In; Lin, Liang-In; Tseng, Li-Hui; KUN-HUEI YEH; Tseng, Li-Hui; Chang, Yih-Leong; YU-LIN LIN; Yeh, Kun-Huei; ANN-LII CHENG; Yeh, Kun-Huei; Cheng, Ann-Lii; Cheng, Ann-Lii; Cheng, Ann-Lii |
| 臺大學術典藏 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Yeh K.-H.; Cheng A.-L.; YIH-LEONG CHANG; Lin L.-I.; Tseng L.-H.; Yu S.-C.; Ou D.-L.; Liau J.-Y.; Lin Y.-L. |
| 臺大學術典藏 |
2020-03-05T12:22:25Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Liau J.-Y.; SHAN-CHI YU; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:33Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:53:55Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-03-10T07:58:45Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; LI-HUI TSENG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 國家衛生研究院 |
2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, LT;Chen, JS;Chao, Y;Tsai, CS;Shan, YS;Hsu, C;Huang, SF;Tsou, HH;Lee, KD;Chiu, CF;Rau, KM;Ho, CL;Yu, MS;Taiwan Cooperative Oncology Group |
| 國立成功大學 |
2013-05-20 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, Li-Tzong; Chen, Jen-Shi; Chao, Yee; Tsai, Chang-Sung; Shan, Yan-Shen; Hsu, Chiun; Huang, Shiu-Feng; Tsou, Hsiao-Hui; Lee, Kuan-Der; Chiu, Chang-Fang; Rau, Kun-Ming; Ho, Ching-Liang; Yu, Ming-Sun |
